MindRank AI ^Company

MindRank AI is a clinical stage AI-powered drug discovery company that aims to accelerate the drug discovery process and deliver small molecule medicines with clinical benefits. They have developed proprietary AI platforms such as PharmKG, Molecule Dance, and Molecule Pro to integrate innovations in machine learning, biology, and chemistry. Their AI-designed drug MDR-001, an oral small-molecule GLP-1 RA, has obtained US IND approval for the treatment of obesity and type 2 diabetes mellitus. MindRank has also successfully delivered an allosteric inhibitor PCC with Best-in-Class potential to a biotech company. Through their proprietary AI platform, they strive to deliver small molecule drugs with superior potency, druggability, and novelty.